medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Efficacy and safety of TiNO-coated stents versus drug-eluting coronary stents. Systematic literature review and meta-analysis.

Frederic C. Daoud, MD, MSc[a], Louis Létinier, MD, MSc[a], Nicholas Moore, MD, PhD[a], Pierre Coste, MD[b], Pasi P. Karjalainen, MD, PhD[c]

Short title: TiNO-coated stents *versus* DES meta-analysis

Affiliations

[a] Univ. Bordeaux, INSERM, BPH, U1219, F-33000, Bordeaux, France

[b] Coronary Care Unit, Cardiologic Hospital, University of Bordeaux, Pessac, France

[c] Cardiac unit, Heart and Lung Center, Helsinki University Hospital and Helsinki University, Helsinki, Finland

Address for correspondence

Frederic C. Daoud, M.D., M.Sc.
orcid.org/0000-0002-0469-9723
Université de Bordeaux
Unité de Pharmacologie clinique
INSERM U1219 Bordeaux Population Health Center
Bâtiment 1A, 1er étage, Case 36
146 rue Léo Saignat
33076 Bordeaux Cedex, France
Tel. +33 (0)5 57 57 15 60, Fax +33 (0)5 57 57 46 71 06
E-mail: frederic.daoud-pineau@u-bordeaux.fr

Manuscript file word count: 5,843

Figures: 3

Tables: 2

Abstract word count: 295

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract

Objectives: To compare clinical outcomes after percutaneous coronary intervention (PCI) using titanium-nitride-oxide coated stents (TiNOS) versus drug-eluting stents (DES) in coronary artery disease (CAD) including acute coronary syndrome (ACS).

Design: Prospective systematic literature (SLR) conducted according to PRISMA. Medline, Embase, Cochrane, Web of Science were searched in March 2018 and updated.

Setting: Interventional cardiology.

Participants: Patients with CAD, including ACS, requiring PCI.

Interventions: All prospective randomized controlled trials (RCTs) that compared clinical outcomes after PCI with DES versus TiNOS.

Outcome measures: The pooled risk ratios (RR), TiNOS over DES, with 95% confidence intervals (CI) are computed for device-oriented Major Adverse Cardiac Events (MACE), non-fatal myocardial infarction (MI), cardiac death (CD), clinically driven target lesion revascularization (TLR), probable or definite stent thrombosis (ST), total mortality, at one to five years after PCI. Pooled RRs are stratified according to baseline ACS versus other CAD. Sensitivity analysis (SA) and certainty of the evidence are rated per GRADE.

Results: Five RCTs are eligible with 1,855 patients with TiNOS versus 1,363 with DES at 1-year follow-up and 783 versus 771 at 5-year. Three RCTs included patients with ACS only. One-year RRs in ACS are: MACE 0.93 [0.72, 1.20], MI 0.48 [0.31, 0.73], CD 0.66 [0.33, 1.31], TLR 1.55 [1.10, 2.19] and ST 0.35 [0.20, 0.64]. One-year MACE, MI, and ST are robust to SA. The certainty of the evidence is high in MACE, moderate in MI, and low or very low in the other endpoints. There are too few observations to conclude about other CAD and 5-year outcomes. However, 5-year interim results are consistent with 1-year conclusions.

Conclusions: A similar risk of MACE is found in TiNOS and DES, with potentially fewer MI and ST but more TLR in TiNOS. TiNOS are safe and effective in ACS at 1-year follow-up.

Registration: PROSPERO CRD42018090622

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Strengths and limitations of this study

- Strengths:
  - The level of certainty of the evidence is high for the primary endpoint at one-year follow-up in patients treated for acute coronary syndrome.
  - The primary endpoint and critical secondary endpoints are robust to sensitivity analysis.
- Limitations:
  - Outcomes in patients treated for chronic coronary artery disease cannot be analyzed.
  - The level of certainty of the evidence of secondary endpoints is moderate or low.
  - Analysis of five-year outcomes is still at an interim stage.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Objectives

Percutaneous coronary interventions (PCI) with drug-eluting stents (DES) is the standard of care in Coronary Artery Disease (CAD), including Acute Coronary Syndrome (ACS).[1-6] mTOR inhibitors such as everolimus and paclitaxel have been the main drug types used on stents to inhibit post-stenting restenosis.[7-9] Their side effect is the increased risk of stent thrombosis (ST), requiring prolonged Dual AntiPlatelet Therapy (DAPT) with its own risk of complications.[10,11] Titanium-nitride-oxide coated coronary stents (TiNOS), also designated "bioactive stents" (BAS) have a pharmacologically inactive, non-absorbable coating. Preclinical data has shown less neointimal hyperplasia with TiNOS than with bare-metal stents (BMS).[12,13,14]
Several trials comparing TiNOS with DES have been conducted but no systematic review of that evidence has been published so far.

Participants – Interventions - Outcome measures

The question was specified using the PICOS framework[15]: **P**atients presented CAD including ACS. **I**ntervention was PCI using TiNOS. **C**omparator was PCI using DES. **O**utcomes were the device-oriented Major Adverse Cardiac Events (MACE) and the components of that composiste i.e., Cardiac death (CD), recurrent myocardial infarction (MI), and clinically driven target lesion revascularization (TLR). Probable or definite ST, and all-cause mortality ("total death": TD) were also analyzed. Outcomes were assessed at 1-year and 5-year follow-ups. **S**tudy methods were prospective randomized controlled clinical trials (RCTs).

Methods

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

This systematic literature review (SLR) is the first to compare the efficacy and safety of TiNOS *versus* DES in CAD. It was designed and conducted according to methods described in the Cochrane Handbook with the use of "Grading of Recommendations Assessment, Development and Evaluation" (GRADE). The protocol was registered in PROSPERO (CRD4201809062) before initiation. It is reported according to "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA).[16-18]

Data recording and the meta-analysis were conducted in RevMan 5.3 (Review Manager Version 5.3 software. Copenhagen, Denmark: The Nordic Cochrane Centre, 2014). The certainty of evidence according was rated with GRADEpro GDT software 2020 on-line version, (https://gradepro.org). Additional analyses were performed in STATA 16 (StataCorp LP, College Station, Tx, USA) using the metan and metaprop packages.

Data sources

MEDLINE, EMBASE, the Cochrane Library, and Web of Science (WoS) electronic databases, were queried on March 8, 2018, using their search engines. The search terms were: *((bioactive OR (Titanium AND nitride AND oxide) OR TiNO OR TNO OR BAS) AND stent) AND (DES OR (drug AND eluting AND stent)) AND (RCT OR ((randomized OR randomised) AND controlled AND trial))*. No exclusion filter was applied related to language, country, year, or any other aspect. The websites of AHA, TCT, ESC, EuroPCR, and clinicaltrials.gov were also searched. The queries were updated on July 22, 2020, when all initially identified RCTs were published to retrieve new evidence if any, from RCTs meeting the PICOS specifications of this SLR.

The downloaded record files were imported and pooled and sifted in EndNote X8 (Clarivate Analytics, Philadelphia, PA, USA). One reference only was selected when duplicates were

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

identified. When differerent references concerned the same study, their information was pooled using the citation of the most recent one. Full articles were reviewed for all references.

Study selection and Data extraction

Two reviewers (FD and LL) performed independently the following steps: (1)Exhaustive reference screening, (2)Reference classification according to the inclusion and exclusion criteria, (3)Extraction of study methods, (4)Patient baseline data, (5)Treatment data and results of each eligible RCT, (6)Individual eligible RCT risk of bias rating, (7)Assessment of the certainty of the evidence for each outcome variable according to GRADE. The results were recorded in RevMan 5.3 file.

Differences were adjudicated by a third reviewer (NM). The similarity of the definitions of endpoints across the RCTs was discussed with one investigator (PK). The risk of bias of individual RCTs was rated according to the criteria proposed by the Cochrane Collaboration with operator blinding as a separate item.

The screened studies were included if they met the following criteria: First-hand clinical evidence with prospective inclusion; patients with CAD treated with coronary PCI; implantation of either TiNOS or DES after the random allocation of the stent type; target outcomes reported at 1-year and/or 5-year follow-up; the outcomes reported as the number of patients who were included along with the number or proportion of them who presented an event of interest.

Studies were ruled out if any of the study selection criteria were not met or if IRB/ethics committee approval and patient informed consent were not explicitly required.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

The term ACS referred to patients who presented at baseline with ST-elevated myocardial infarction (STEMI), or non-ST-elevated myocardial infarction (NSTEMI), or unstable angina pectoris.

The definitions of outcomes aimed in this SLR protocol are those defined by the Academic Research Consortium (ARC).[19] Data extraction is stratified according to patient clinical presentation, i.e., ACS *versus* with other CAD.

Statistical analysis

The two treatment arms are compared for each endpoint using the risk ratio (RR) defined as *((n patients with an event in TiNOS)/(n patients in TiNOS))/((n patients with an event in DES)/(n patients in DES))*. As a result, RR > 1 reflects a higher frequency of events in the TiNOS arm than in the DES arm and conversely. Outcomes are analyzed on an intention-to-treat (ITT) basis. The numerator is the number of patients presenting an event and counted in the treatment arm they were randomized to and the denominator is the sample size of the corresponding arm.

For each endpoint, individual study RRs are calculated with their 95% confidence interval (CI [,]) and their degree of heterogeneity is determined. If no significant heterogeneity is detected, the pooled RR is calculated with its CI using the M-H method with a fixed-effect model.[16,20,21] In the case of significant heterogeneity, pooling uses the M-H method with a random-effects model. The pooled analysis is stratified according to baseline clinical presentation, ACS *versus* other CAD. One-year and 5-year outcomes are analyzed separately. Sensitivity analysis is performed by iteratively recalculating the pooled RR after removing one eligible RCT. As a result, the impact of each RCT on the pooled RR is estimated. It estimates the impact of

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

differences in stent generations and the potential risk of indirection related to differences in outcome definitions.

Patient and public involvement

No patient involved.

Results

Overall

Study identification, screening, and selection are described in the PRISMA flowchart (Figure 1). One hundred and eleven references were identified and nine publications with first-hand data about five RCTs are eligible for inclusion in the meta-analysis.

The number of patients with 1-year follow-up data is 1,855 in the TiNOS arm *versus* 1,363 in the DES arm. Those numbers are 783 *versus* 773 patients at 5-year follow-up. Three RCTs enrolled only patients presenting with ACS and two enrolled and analyzed jointly patients presenting with ACS and other CAD. TIDE enrolled 143 patients with ACS (47%) and TITANIC-XV, 112 (64.7%). The baseline characteristics are summarized in Table 1. Funnel plots and Harbord tests did not detect a risk of publication bias concerning any of the endpoints at 1-year follow-up in all CAD (supplemental material).

Four RCTs report or enable to deduct the number of cases of clinically driven TLR, CD, non-fatal recurrent MI, and the composite of CD or any non-fatal MI extended or clinically driven TLR. This results in a modified device-oriented MACE where MI “not clearly attributable to a nontarget vessel” is replaced by any MI. Given fatal MIs are counted as CD, this modification adds non-fatal MI in nontarget vessels.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

In one RCT (TITANIC-XV), the primary endpoint is estimated from the available data as the sum of CD, any non-fatal MI, and any TLR assuming no overlap between those variables.

The risk of bias in individual RCTs is rated moderate or low except for the operator's knowledge of the type of stent used during the intervention in all RCTs.

The pooled RRs of all outcomes at 1-year and 5-year follow-up are reported in Table 2 with CIs and sensitivity analyses. Results are reported overall and in the ACS subgroup. Given the 5-year follow-up of patients in the TIDES-ACS trial is ongoing, pooled RRs for 5-year outcomes are interim results.

The stratified (ACS relative to other CAD) pooled RRs of effectiveness endpoints show no significant difference in 1-year MACE and a significantly higher rate of TLR with TiNOS (Figure 2). The stratified stratified pooled RRs of safety endpoints show no significant difference in 1-year CD, but significantly lower rates in non-fatal, MI and ST with TiNOS compared to DES (Figure 3). The pooled RR of TD is also not significant (supplemental file).

The stratified pooled RRs analysis shows a much larger number of patients in the ACS subgroup compared to the other CAD subgroup (85.2% *versus* 14.8%). The overall effects are driven by the ACS subgroup. The results of the other CAD subgroup (TIDE and TITANIC-XV) are not interpretable because outcomes in patients with ACS are not reported separately. Therefore, the subsequent steps of this SLR are refocused on RCT about ACS only.

ACS at 1-year follow-up

The pooled RRs of effectiveness and safety endpoints in MACE are consistent with overall results but heterogeneity, robustness to sensitivity analysis (Table 2) and the level of certainty of

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

the underlying evidence according to GRADE (supplemental material) need to be assessed separately.

The RR of MACE presents no significant heterogeneity, is robust to sensitivity analysis, and the certainty of evidence is rated high. The RR of clinically driven TLR presents no significant heterogeneity but results are not robust to sensitivity analysis, and the certainty of the evidence is rated low.

The pooled RRs of CD and TD present significant heterogeneity, are not robust to sensitivity analysis, and the certainty of the evidence is rated very low.

The pooled RR of non-fatal MI presents no significant heterogeneity, is robust to sensitivity analysis, and the certainty of the evidence is rated moderate.

The pooled RR of probable or definite SE presents no significant heterogeneity, is robust to sensitivity analysis, and the certainty of the evidence is rated low.

Discussion

TIDE and TITANIC-XV enrolled 255 patients with ACS but their data are not reported separately from the other patients. The impact of not including them in the ACS subgroup is limited given they represent 7.9% of all patients with ACS. The modified definition of device-oriented MACE results in including non-fatal MIs from nontarget vessels. One can reasonably assume the index stent does not affect those events. Ninety non-fatal MIs are reported. Assuming half of them are related to nontarget vessels (i.e., 45 cases), proportionality with sample size would lead to 27 fewer cases with TiNOS and 18 with DES, which would result in an RR of 0.19 [0.09, 0.42]. The inclusion of nontarget MIs thus results in a dilution that is favorable to DES. If the same numbers cases were removed from the count of MACE, the RR would be 0.98 [0.73,

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

1.30], which would not change the non-inferiority conclusion. The robustness to sensitivity analysis of the pooled RRs of MACE, MI, and ST in ACS, shows that the differences in DES generations, including the elution of paclitaxel and mTOR inhibitors do not significantly change those results. The interim 5-year pooled results will be updated when the final results of TIDES-ACS are published, but the current results are consistent with 1-year outcomes.

Conclusions

This systematic literature review shows that titanium-nitride oxide coated-coronary stents and drug-eluting stents have a similar risk of device-oriented major adverse cardiac events at one-year follow-up in patients with an acute coronary syndrome. This result is robust and the level of certainty of the evidence is high. It also shows a lower risk of recurrent myocardial infarction and stent thrombosis with titanium-nitride oxide coated-coronary stents than with drug-eluting stents with a potentially higher risk of target lesion revascularization. Interim five-year pooled outcomes are consistent with one-year outcomes. These results show that the titanium-nitride oxide coated-coronary stents are safe and effective in acute coronary syndrome at one-year follow-up.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 1 Baseline characteristics

Study	**Age & prior events**			**Clinical presentation**			**Procedural data & medication**			**Attrition & cross-overs**
Stent		TiNOS	DES		TiNOS	DES		TiNOS	DES	
TITAX-AMI[22,23] [NCT00495664]	Patients n age prior MI prior PCI prior CABG	214 64±11 15% 10% 7%	211 64±11 9% 5% 6%	NSTEMI STEMI	61% 39%	54% 46%	stents in culprit lesion n TSL (mm) post-dilation procedural success DAPT 12-months	1.1±0.3 18.5±6.4 42% 99.5% 31%	1.1±0.4 19.2±7.2 35% 98.1% 65%	LFU 1y TiNOS: 0 DES: 0 5y TiNOS 3 DES: 7
TIDE[24] [NCT00492908]	Patients n age prior MI prior PCI prior CABG	152 65.9±9.0 27.6% 25.7% 7.9%	150 63.4±10.5 28.7% 21.3% 25.3% 2.7%	Stable CAD NSTEMI Unstable angina	57.9% 32.9% 9.2%	47.3% 42.0% 10.7%	stents in culprit lesion n TSL (mm) device success DAPT 12-months	1.28±0.55 19.3±11.1 93.0%	1.17±0.45 19.6±10.0 94.6%	LFU 1y TiNOS: 0 DES: 2 5y : N.R.
TITANIC-XV[25] [NCT01510509]	Patients n age prior MI prior PCI prior CABG	83 66.5±8.8 10.8% 8.4% 2.4%	90 64.5±10.1 15.6% 11.1% 2.2%	NST ACS Deducted other CAD	69.9% 30.1%	60.0% 40.0%	stents in culprit lesion n TSL (mm) stent failure DAPT 12 months	1.1±0.3 18.72±8.20 N.R.	1.1±0.3 21.63±9.65 N.R.	N.R.
BASE-ACS[26,27] [NCT00819923]	patients age prior MI prior PCI prior CABG	417 63±12 13.4% 9.6% 4.8%	410 63±12 9.8% 10.5% 4.1%	NSTEMI STEMI Unstable angina	49.4% 38.8% 11.8%	45.6% 38.8% 15.6%	stents in culprit lesion n TSL (mm) post-dilation stent failure DAPT : Aspirin : protocol indefinite, actual N.R. Clopidogrel: protocol 6 months, actual N.R.	1.15±0.38 20.8±9.4 42.2% 0.0%	1.14±0.36 20.6±8.2 43.9% 1.0%	LFU 1y TiNOS: 3 DES: 3 5y TiNOS 29 DES: 28
TIDES-ACS[28,29] [NCT02049229]	Patients n age prior MI prior PCI prior CABG	989 62.7±10. 7.6% 7.0% 0.6%	502 62.6±10.5 9.0% 6.6% 1.2%	NSTEMI STEMI	46.3% 44.9%	45.0% 47.6%	stents in culprit lesion n TSL (mm) post-dilation stent failure DAPT 12-months	1.13±0.38 20.5±7.8 33.0% 0.3% 80.3%	1.14±0.37 20.6±7.2 38.0% 1.0% 86.0%	LFU 1y TiNOS: 7 DES: 4

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 2 Pooled outcomes with sensitivity analysis

	M-H fixed effects RR & 95% CI after the removal of:					
Endpoint	**None: all RCTs included**	**TITAX-AMI**	**TIDE**	**TITANIC-XV**	**BASE-ACS**	**TIDES-ACS**
ALL CAD: ACS & Other CAD – 1 year follow-up						
MACE	1.01 [0.81, 1.26]	1.06 [0.83, 1.36]	0.96 [0.75, 1.23]	0.98 [0.78, 1.24]	0.99 [0.76, 1.29]	1.07 [0.82, 1.40]
CD or MI	0.55 [0.39, 0.77]	0.57 [0.39, 0.82]	0.52 [0.36, 0.74]	0.55 [0.39, 0.77]	0.53 [0.36, 0.79]	0.60 [0.40, 0.91]
Non-fatal MI	0.52 [0.36, 0.76]	0.51 [0.33, 0.78]	0.48 [0.31, 0.73]	0.52 [0.35, 0.76]	0.60 [0.38, 0.93]	0.51 [0.32, 0.82]
CD	0.66 [0.33, 1.31]	0.77 [0.37, 1.61]	0.66 [0.33, 1.31]	0.66 [0.33, 1.31]	0.30 [0.11, 0.81]	1.11 [0.43, 2.85]
Clinically driven TLR	1.62 [1.20, 2.18]	1.56 [1.13, 2.15]	1.60 [1.15, 2.24]	1.58 [1.16, 2.14]	1.74 [1.22, 2.47]	1.63 [1.14, 2.33]
Probable or definite ST	0.39 [0.22, 0.69]	0.46 [0.25, 0.84]	0.35 [0.20, 0.64]	0.39 [0.22, 0.69]	0.36 [0.18, 0.72]	0.38 [0.16, 0.87]
Definite ST	0.51 [0.26, 0.99]	0.49 [0.25, 0.97]	0.46 [0.23, 0.92]	0.51 [0.26, 0.99]	0.62 [0.29, 1.36]	0.52 [0.18, 1.44]
TD	0.78 [0.48, 1.27]	0.77 [0.46, 1.32]	0.78 [0.47, 1.27]	0.78 [0.48, 1.27]	0.49 [0.26, 0.95] [b]	1.22 [0.65, 2.28]
ACS only – 1 year follow-up						
MACE	0.93 [0.72, 1.20]	0.97 [0.73, 1.30]	N.A.	N.A.	0.86 [0.63, 1.19]	0.95 [0.68, 1.33]
CD or MI	0.52 [0.36, 0.75]	0.53 [0.35, 0.80]	N.A.	N.A.	0.48 [0.30, 0.75]	0.56 [0.35, 0.90]
Non-fatal MI	0.48 [0.31, 0.73]	0.45 [0.27, 0.74]	N.A.	N.A.	0.55 [0.33, 0.92]	0.44 [0.25, 0.77]
CD	0.66 [0.33, 1.31]	0.77 [0.37, 1.61]	N.A.	N.A.	0.30 [0.11, 0.81]	1.11 [0.43, 2.85]
Clinically driven TLR	1.55 [1.10, 2.19]	1.46 [0.99, 2.15]	N.A.	N.A.	1.69 [1.09, 2.63]	1.53 [0.97, 2.40]
Probable or definite ST	0.35 [0.20, 0.64]	0.42 [0.22, 0.78]	N.A.	N.A.	0.32 [0.15, 0.65]	0.31 [0.12, 0.77]
Definite ST	0.46 [0.23, 0.92]	0.43 [0.21, 0.89]	N.A.	N.A.	0.54 [0.24, 1.24]	0.39 [0.12, 1.25]
TD	0.78 [0.47, 1.27]	0.77 [0.45, 1.32]	N.A.	N.A.	0.47 [0.24, 0.93] [b]	1.23 [0.64, 2.35]
ALL CAD: ACS & Other CAD – 5 year follow-up - Interim Results						
MACE	0.82 [0.66, 1.02]	0.91 [0.70, 1.19]	0.74 [0.58, 0.95] [b]	N.A.	0.83 [0.62, 1.10]	Expected
CD or MI	0.57 [0.42, 0.77]	0.67 [0.46, 0.97]	0.53 [0.38, 0.73]	N.A.	0.53 [0.35, 0.80]	Expected
Non-fatal MI	0.56 [0.39, 0.80]	0.59 [0.37, 0.92]	0.54 [0.37, 0.80]	N.A.	0.57 [0.35, 0.93]	Expected
CD	0.68 [0.39, 1.19]	0.93 [0.47, 1.82]	0.59 [0.31, 1.11]	N.A.	0.55 [0.25, 1.24]	Expected
Clinically driven TLR	1.01 [0.75, 1.35]	1.00 [0.71, 1.42]	0.94 [0.66, 1.32]	N.A.	1.13 [0.77, 1.66]	Expected
Probable or definite ST	0.30 [0.14, 0.61]	0.45 [0.19, 1.05]	0.25 [0.12, 0.55]	N.A.	0.22 [0.07, 0.70]	Expected
Definite ST	0.25 [0.11, 0.55]	0.37 [0.14, 0.99]	0.20 [0.09, 0.49]	N.A.	0.22 [0.07, 0.70]	Expected
TD	1.03 [0.74, 1.45]	1.14 [0.75, 1.73]	0.95 [0.65, 1.37]	N.A.	1.05 [0.65, 1.69]	Expected
ACS only – 5 year follow-up - Interim Results						
MACE [a]	0.74 [0.58, 0.95]	0.81 [0.59, 1.12] [c]	N.A.	N.A.	0.65 [0.44, 0.95] [c]	Expected
CD or MI	0.53 [0.38, 0.73]	0.61 [0.40, 0.95]	N.A.	N.A.	0.42 [0.25, 0.71]	Expected
Non-fatal MI	0.54 [0.37, 0.80]	0.56 [0.33, 0.94] [c]	N.A.	N.A.	0.53 [0.30, 0.94] [c]	Expected
CD	0.59 [0.31, 1.11]	0.83 [0.38, 1.84] [c]	N.A.	N.A.	0.33 [0.11, 1.00] [c]	Expected
Clinically driven TLR	0.94 [0.66, 1.32]	0.88 [0.56, 1.37] [c]	N.A.	N.A.	1.03 [0.60, 1.76] [c]	Expected
Probable or definite ST [a]	0.25 [0.12, 0.55]	0.37 [0.15, 0.93] [c]	N.A.	N.A.	0.13 [0.03, 0.57] [c]	Expected
Definite ST [a]	0.20 [0.09, 0.49]	0.28 [0.09, 0.85] [c]	N.A.	N.A.	0.13 [0.03, 0.57] [c]	Expected
TD	0.95 [0.65, 1.37]	1.02 [0.63, 1.65] [c]	N.A.	N.A.	0.85 [0.48, 1.53] [c]	Expected

[a] sensitivity analysis in ACS at 5-year follow-up results in the RR and confidence intervals of individual RCTs; [b] borderline shift with 3 or fewer RCTs contributing to the pooled estimate; [c] results based on a single-trial; N.A. Not applicable

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Supplemental material:

- Details of methods applied in this SLR.
- Methods of individual RCTs
- Table of the number of patients with events – ITT
- Funnel plots and results of Harbord tests.
- Summary of risk of bias in individual RCTs
- Pooled RR of CD or MI, and TD
- GRADE certainty of evidence assessment
- PRISMA checklist

Contributors

Frederic Daoud (FD): Main reviewer and meta-analyst with LL.

Louis Létinier (LL): Main reviewer and meta-analyst with with FD.

Nicholas Moore (NM): Third reviewer. Adjudicated disagreements.

Pierre Coste (PC): Advised on protocol and analysis.

Pasi Karjalainen (PK): Provided additional information about the methods of the individual trials.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Funding

This work was exclusively funded by the University of Bordeaux and INSERM BPH U1219, Bordeaux, France

Data sharing statement

All data included in this review are published.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

References

1. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Ting H, O'Gara PT, Kushner FG, Ascheim DD, Brindis RG, Casey Jr DE 1 , Chung MK, de Lemos JA, Diercks DB, Fang JC, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011 Dec 6; 124(23):e574-651. doi: 10.1161/CIR.0b013e31823ba622. Epub 2011 Nov 7. Erratum in: Circulation. 2012 Feb 28;125(8):e412. Dosage error in article text. PMID: 22064601.

2. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Jan 29; 127(4):e362-425. doi: 10.1161/CIR.0b013e3182742cf6. Epub 2012 Dec 17. Erratum in: Circulation. 2013 Dec 24;128(25):e481. PMID: 23247304.

3. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34(38):2949–3003. doi: 10.1093/eurheartj/eht296. Epub 2013 Aug 30. Erratum in: Eur Heart J. 2014 Sep 1;35(33):2260-1. PMID: 23996286.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

4. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ; ACC/AHA Task Force Members; Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130(25):2354-2394. doi: 10.1161/CIR.0000000000000133. Epub 2014 Sep 23. Erratum in: Circulation. 2014 Dec 23;130(25):e431-2. Dosage error in article text. PMID: 25249586.

5. Collet J, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt D, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale C, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis B, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten F, Sibbing D, Siontis G, ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020 Aug 29; ehaa575. doi: 10.1093/eurheartj/ehaa575. Epub ahead of print. PMID: 32860058.

6. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2):119-177. doi: 10.1093/eurheartj/ehx393. PMID: 28886621.

8. Wessely R, Schömig A, Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol. 2006; 47(4):708-714. doi: 10.1016/j.jacc.2005.09.047. Epub 2006 Jan 26. PMID: 16487832.

8. Patterson C, Mapera S, Li HH, Madamanchi N, Hilliard E, Lineberger R, Herrmann R, Charles P. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol. 2006; 26(7):1473-1480. doi: 10.1161/01.ATV.0000223866.42883.3b. Epub 2006 Apr 27. PMID: 16645158.

9. Yazdani SK, Sheehy A, Pacetti S, Rittlemeyer B, Kolodgie FD, Virmani R. Stent Coating Integrity of Durable and Biodegradable Coated Drug Eluting Stents. J Interv Cardiol. 2016; 29(5):483-490. doi: 10.1111/joic.12303. Epub 2016 Jun 10. PMID: 27282892.

10. Costa F, Van Klaveren D, Feres F, James S, Räber L, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M; PRECISE-DAPT Study Investigators. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. J Am Coll Cardiol. 2019; 73(7):741-754. doi: 10.1016/j.jacc.2018.11.048. PMID: 30784667.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

11. Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary Intervention Intern Med. 2020; 59(3):311-321. doi: 10.2169/internalmedicine.3685-19. Epub 2019 Oct 7. PMID: 31588089; PMCID: PMC7028427.

12. Windecker S, Mayer I, De Pasquale G, Maier W, Dirsch O, De Groot P, Wu YP, Noll G, Leskosek B, Meier B, Hess OM; Working Group on Novel Surface Coating of Biomedical Devices (SCOL). Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation. 2001; 104(8):928-933. doi: 10.1161/hc3401.093146. PMID: 11514381.

13. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, del Soldato P. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A. 2001; 98(7):4202-4208. doi: 10.1073/pnas.071054698. Epub 2001 Mar 20. PMID: 11259671; PMCID: PMC31203.

14. Windecker S, Simon R, Lins M, Klauss V, Eberli FR, Roffi M, Pedrazzini G, Moccetti T, Wenaweser P, Togni M, Tüller D, Zbinden R, Seiler C, Mehilli J, Kastrati A, Meier B, Hess OM. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation. 2005; 111(20):2617-2622. doi: 10.1161/CIRCULATIONAHA.104.486647. Epub 2005 May 9. PMID: 15883209.

15. Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for clinical questions. AMIA Annu Symp Proc. 2006; 2006:359-363. PMID: 17238363; PMCID: PMC1839740.

16. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. www.cochrane-handbook.org, version 5.1.0 updated March 2011.

17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. doi: 10.1136/bmj.b2700. PMID: 19622552; PMCID: PMC2714672.

18. Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from guidelinedevelopment.org/handbook.

19. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW; Academic Research Consortium.. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document.. Eur Heart J. 2018 Jun 14;39(23):2392–2207. doi: 10.1093/eurheartj/ehy223.; PMID: 29897428.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. doi: 10.1016/0197-2456(86)90046-2. PMID: 3802833.

21. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010; 1(2):97-111. doi: 10.1002/jrsm.12. Epub 2010 Nov 21. PMID: 26061376.

22. Karjalainen PP, Ylitalo A, Niemelä M, Kervinen K, Mäkikallio T, Pietili M, Sia J, Tuomainen P, Nyman K, Airaksinen KE. Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI trial. EuroIntervention. 2008; 4(2):234-241. doi: 10.4244/eijv4i2a42. PMID: 19110789.

23. Tuomainen PO, Ylitalo A, Niemelä M, Kervinen K, Pietilä M, Sia J, Nyman K, Nammas W, Airaksinen KE, Karjalainen PP. Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction: long-term follow-up from the TITAX AMI trial. Int J Cardiol. 2013; 168(2):1214-1219. doi: 10.1016/j.ijcard.2012.11.060. Epub 2012 Dec 3. PMID: 23218575.

24. Pilgrim T, Räber L, Limacher A, Löffel L, Wenaweser P, Cook S, Stauffer JC, Togni M, Vogel R, Garachemani A, Moschovitis A, Khattab AA, Seiler C, Meier B, Jüni P, Windecker S. Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial. JACC Cardiovasc Interv. 2011; 4(6):672-682. doi: 10.1016/j.jcin.2011.02.017. PMID: 21700254.

25. López-Mínguez JR, Nogales-Asensio JM, Doncel-Vecino LJ, Merchán-Herrera A, Pomar-Domingo F, Martínez-Romero P, Fernández-Díaz JA, Valdesuso-Aguilar R, Moreu-Burgos J, Díaz-Fernández J; members of the TITANIC XV Working Group. A randomized study to compare bioactive titanium stents and everolimus-eluting stents in diabetic patients (TITANIC XV): 1-year results. Rev Esp Cardiol (Engl Ed). 2014; 67(7):522-530. doi: 10.1016/j.rec.2013.10.021. Epub 2014 Apr 3. PMID: 24952391.

26. Karjalainen PP, Nammas W, Ylitalo A, de Bruyne B, Lalmand J, de Belder A, Rivero-Crespo F, Kervinen K, Airaksinen JKE. Long-term clinical outcome of titanium-nitride-oxide-coated stents versus everolimus-eluting stents in acute coronary syndrome: Final report of the BASE ACS trial. Int J Cardiol. 2016; 222:275-280. doi: 10.1016/j.ijcard.2016.07.267. Epub 2016 Aug 1. PMID: 27497110.

27. Karjalainen PP, Niemelä M, Airaksinen JK, Rivero-Crespo F, Romppanen H, Sia J, Lalmand J, de Bruyne B, Debelder A, Carlier M, Nammas W, Ylitalo A, Hess OM; BACE-ACS study investigators. A prospective randomised comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial. EuroIntervention. 2012; 8(3):306-315. doi: 10.4244/EIJV8I3A49. PMID: 22829506.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

28. Colkesen EB, Eefting FD, Rensing BJ, Suttorp MJ, Ten Berg JM, Karjalainen PP, Van Der Heyden JA. TIDES-ACS Trial: comparison of titanium-nitride-oxide coated bio-active-stent to the drug (everolimus)-eluting stent in acute coronary syndrome. Study design and objectives. Minerva Cardioangiol. 2015; 63(1):21-29. PMID: 25670057.

29. Tonino PAL, Pijls NHJ, Collet C, Nammas W, Van der Heyden J, Romppanen H, Kervinen K, Airaksinen JKE, Sia J, Lalmand J, Frambach P, Penaranda AS, De Bruyne B, Karjalainen PP; TIDES-ACS Study Group. Titanium-Nitride-Oxide-Coated Versus Everolimus-Eluting Stents in Acute Coronary Syndrome: The Randomized TIDES-ACS Trial. JACC Cardiovasc Interv. 2020; 13(14):1697-1705. doi: 10.1016/j.jcin.2020.04.021. PMID: 32703593.

30. Savović J, Weeks L, Sterne JA, Turner L, Altman DG, Moher D, Higgins JP. Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Syst Rev. 2014; 3:37. doi: 10.1186/2046-4053-3-37. PMID: 24731537; PMCID: PMC4022341.

31. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-926. doi: 10.1136/bmj.39489.470347.AD. PMID: 18436948; PMCID: PMC2335261.

32. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ, Montori VM, Freyschuss B, Vist G, Jaeschke R, Williams JW Jr, Murad MH, Sinclair D, Falck-Ytter Y, Meerpohl J, Whittington C, Thorlund K, Andrews J, Schünemann HJ. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011; 64(12):1283-1293. doi: 10.1016/j.jclinepi.2011.01.012. Epub 2011 Aug 11. PMID: 21839614.

33. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from https://gdt.gradepro.org

34. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials. 1997; 18(6):580-593; discussion 661-6. doi: 10.1016/s0197-2456(97)00051-2. PMID: 9408720.

35. Seeger P, Gabrielsson A. Applicability of the Cochran Q test and the F test for statistical analysis of dichotomous data for dependent samples. Psychol Bull. 1968; 69(4):269-277. doi: 10.1037/h0025667. PMID: 5659656.

36. Gavaghan DJ, Moore RA, McQuay HJ. An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain. 2000; 85(3):415-424. doi: 10.1016/s0304-3959(99)00302-4. PMID: 10781914.

37. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-1558. doi: 10.1002/sim.1186. PMID: 12111919.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

38. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-560. doi: 10.1136/bmj.327.7414.557. PMID: 12958120; PMCID: PMC192859.

39. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-634. doi: 10.1136/bmj.315.7109.629. PMID: 9310563; PMCID: PMC2127453.

40. Egger M, Smith GD. Bias in location and selection of studies. BMJ. 1998; 316(7124):61-66. doi: 10.1136/bmj.316.7124.61. PMID: 9451274; PMCID: PMC2665334.

41. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Publishing Group, 2001:189-208.

42. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006; 25(20):3443-3457. doi: 10.1002/sim.2380. PMID: 16345038.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 1 PRISMA flow chart

Figure 2 Effectiveness endpoints

Figure 3 Safety endpoints

medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

MACE 1-year	TiNOS		DES			Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year
ACS							
TITAX-AMI	22	214	27	211	19.9%	0.80 [0.47, 1.36]	2008
BASE-ACS	40	417	37	410	27.3%	1.06 [0.69, 1.63]	2012
TIDES-ACS	62	989	35	502	33.9%	0.90 [0.60, 1.34]	2020
Subtotal (95% CI)		**1620**		**1123**	**81.1%**	**0.93 [0.72, 1.20]**	
Total events	124		99				
Heterogeneity: Chi² = 0.70, df = 2 (P = 0.71); I² = 0%							
Test for overall effect: Z = 0.55 (P = 0.58)							
Other CAD							
TIDE	27	152	21	150	15.4%	1.27 [0.75, 2.14]	2011
TITANIC-XV	8	83	5	90	3.5%	1.73 [0.59, 5.09]	2011
Subtotal (95% CI)		**235**		**240**	**18.9%**	**1.36 [0.85, 2.17]**	
Total events	35		26				
Heterogeneity: Chi² = 0.26, df = 1 (P = 0.61); I² = 0%							
Test for overall effect: Z = 1.27 (P = 0.21)							
Total (95% CI)		**1855**		**1363**	**100.00%**	**1.01 [0.81, 1.26]**	
Total events	159		125				
Heterogeneity: Chi² = 2.79, df = 4 (P = 0.59); I² = 0%							
Test for overall effect: Z = 0.10 (P = 0.92)							
Test for subgroup differences: Chi² = 1.89, df = 1 (P = 0.17), I² = 47.1%							



clinically driven TLR 1-year	TiNOS		DES			Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year
ACS							
TITAX-AMI	18	214	9	211	13.4%	1.97 [0.91, 4.29]	2008
BASE-ACS	27	417	20	410	29.8%	1.33 [0.76, 2.33]	2012
TIDES-ACS	53	989	17	502	33.3%	1.58 [0.93, 2.70]	2020
Subtotal (95% CI)		**1620**		**1123**	**76.4%**	**1.55 [1.10, 2.19]**	
Total events	98		46				
Heterogeneity: Chi² = 0.67, df = 2 (P = 0.72); I² = 0%							
Test for overall effect: Z = 2.48 (P = 0.01)							
Other CAD							
TIDE	22	152	13	150	19.3%	1.67 [0.87, 3.19]	2011
TITANIC-XV	7	83	3	90	4.2%	2.53 [0.68, 9.46]	2011
Subtotal (95% CI)		**235**		**240**	**23.6%**	**1.83 [1.02, 3.26]**	
Total events	29		16				
Heterogeneity: Chi² = 0.31, df = 1 (P = 0.58); I² = 0%							
Test for overall effect: Z = 2.03 (P = 0.04)							
Total (95% CI)		**1855**		**1363**	**100.00%**	**1.62 [1.20, 2.18]**	
Total events	127		62				
Heterogeneity: Chi² = 1.18, df = 4 (P = 0.88); I² = 0%							
Test for overall effect: Z = 3.16 (P = 0.002)							
Test for subgroup differences: Chi² = 0.22, df = 1 (P = 0.64), I² = 0%							



medRxiv preprint doi: https://doi.org/10.1101/2020.12.19.20248564; this version posted January 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

CD 1-year	TiNOS		DES			Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year
ACS							
TITAX-AMI	1	214	4	211	21.6%	0.25 [0.03, 2.19]	2008
BASE-ACS	8	417	4	410	21.6%	1.97 [0.60, 6.48]	2012
TIDES-ACS	5	989	8	502	56.8%	0.32 [0.10, 0.96]	2020
Subtotal (95% CI)		**1620**		**1123**	**100.0%**	**0.66 [0.33, 1.31]**	
Total events	14		16				
Heterogeneity: Chi² = 5.67, df = 2 (P = 0.06); I² = 65%							
Test for overall effect: Z = 1.19 (P = 0.23)							
Other CAD							
TIDE	0	83	0	90		Not estimable	2011
TITANIC-XV	0	152	0	150		Not estimable	2011
Subtotal (95% CI)		**235**		**240**		**Not estimable**	
Total events	0		0				
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
Total (95% CI)		**1855**		**1363**	**100.00%**	**0.66 [0.33, 1.31]**	
Total events	14		16				
Heterogeneity: Chi² = 5.67, df = 2 (P = 0.06); I² = 65%							
Test for overall effect: Z = 1.19 (P = 0.23)							
Test for subgroup differences: Not applicable							



non-fatal MI 1-year	TiNOS		DES			Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year
ACS							
TITAX-AMI	8	214	14	211	19.4%	0.56 [0.24, 1.32]	2008
BASE-ACS	9	417	24	410	33.2%	0.37 [0.17, 0.78]	2012
TIDES-ACS	18	989	17	502	31.0%	0.54 [0.28, 1.03]	2020
Subtotal (95% CI)		**1620**		**1123**	**83.5%**	**0.48 [0.31, 0.73]**	
Total events	35		55				
Heterogeneity: Chi² = 0.72, df = 2 (P = 0.70); I² = 0%							
Test for overall effect: Z = 3.41 (P = 0.0006)							
Other CAD							
TIDE	8	152	10	150	13.8%	0.79 [0.32, 1.95]	2011
TITANIC-XV	1	83	2	90	2.6%	0.54 [0.05, 5.87]	2011
Subtotal (95% CI)		**235**		**240**	**16.5%**	**0.75 [0.32, 1.74]**	
Total events	9		12				
Heterogeneity: Chi² = 0.08, df = 1 (P = 0.77); I² = 0%							
Test for overall effect: Z = 0.67 (P = 0.50)							
Total (95% CI)		**1855**		**1363**	**100.00%**	**0.52 [0.36, 0.76]**	
Total events	44		67				
Heterogeneity: Chi² = 1.67, df = 4 (P = 0.80); I² = 0%							
Test for overall effect: Z = 3.37 (P = 0.0007)							
Test for subgroup differences: Chi² = 0.89, df = 1 (P = 0.35), I² = 0%							



probable definite ST 1-year	TiNOS		DES			Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year
ACS							
TITAX-AMI	1	214	8	211	21.1%	0.12 [0.02, 0.98]	2008
BASE-ACS	5	417	11	410	29.0%	0.45 [0.16, 1.27]	2012
TIDES-ACS	11	989	14	502	48.6%	0.40 [0.18, 0.87]	2020
Subtotal (95% CI)		**1620**		**1123**	**98.7%**	**0.35 [0.20, 0.64]**	
Total events	17		33				
Heterogeneity: Chi² = 1.28, df = 2 (P = 0.53); I² = 0%							
Test for overall effect: Z = 3.41 (P = 0.0006)							
Other CAD							
TITANIC-XV	0	83	0	90		Not estimable	2011
TIDE	1	152	0	150	1.3%	2.96 [0.12, 72.11]	2011
Subtotal (95% CI)		**235**		**240**	**1.3%**	**2.96 [0.12, 72.11]**	
Total events	1		0				
Heterogeneity: Not applicable							
Test for overall effect: Z = 0.67 (P = 0.51)							
Total (95% CI)		**1855**		**1363**	**100.0%**	**0.39 [0.22, 0.69]**	
Total events	18		33				
Heterogeneity: Chi² = 2.81, df = 3 (P = 0.42); I² = 0%							
Test for overall effect: Z = 3.23 (P = 0.001)							
Test for subgroup differences: Chi² = 1.64, df = 1 (P = 0.20), I² = 39.1%